Portal de Periódicos da CAPES

Ledipasvir and Sofosbuvir in the Treatment of Early Hepatitis C Virus Infection in HIV-Infected Men

2018; Oxford University Press; Volume: 5; Issue: 10 Linguagem: Inglês

10.1093/ofid/ofy238

2328-8957

Paari M Palaniswami, Ahmed El Sayed, Benjamin Asriel, Jesse R Carollo, Daniel S. Fierer, Bisher Akil, Juan Bailey, Paul Bellman, Daniel T. Bowers, Krisczar Bungay, Susanne Burger, Aviva Cantor, Rachel Chasan, Robert Chavez, Rita Chow, Robert M. Cohen, Patrick Dalton, John Dellosso, Stephen M. Dillon, Eileen Donlon, Terry Farrow, Jose Fefer, Michael Gaisa, Rodolfo Guadron, Stuart Haber, Susan Hefron, Lawrence Higgins, Lawrence Hitzeman, Ricky Hsu, Shirish Huprikar, Victor Inada, Sneha Jacob, Livette Johnson, Barbara Johnston, Donald Kaminsky, Oscar Klein, Jeffrey Kwong, José Lares-Guia, E. H. Leach, Randy L. Levine, Irina Linetskaya, Л. С. Литвинова, Amisha Malhotra, William Mandell, Martin Markowitz, Gal Mayer, Eddie Meraz, Erik Mortensen, Joseph Olivieri, Charles Paolino, Punyadech Photangtham, George Psevdos, Asa Radix, Steven Rapaport, Roona Ray, Gabriela Rodriguez-Caprio, William Shay, Nirupama Somasundaram, Lembitu Sorra, Richie Tran, Antonio Urbina, Rona M. Vail, Francis Wallach, Wen Wang, Susan R. Weiss, Melissa Wiener,

Liver Disease Diagnosis and Treatment

Abstract Background Treatment of HIV-infected men during early hepatitis C virus (HCV) infection with interferon results in a higher cure rate with a shorter duration of treatment than during chronic HCV infection. We recently demonstrated that this phenomenon applied to interferon-free treatment as well, curing most participants with short-course sofosbuvir and ribavirin. Due to the significantly higher potency of the ledipasvir/sofosbuvir (LDV/SOF) combination, we hypothesized that we would be more successful in curing early HCV infections using a shorter course of LDV/SOF than that used for treating chronic HCV infections. Methods We performed a prospective, open-label, consecutive case series study of 8 weeks of LDV/SOF in HIV-infected men with early genotype 1 HCV infection. The primary end point was aviremia at least 12 weeks after completion of treatment. Results We treated 25 HIV-infected men with early sexually acquired HCV infection with 8 weeks of LDV/SOF, and all 25 (100%) were cured. Twelve (48%) reported sexualized drug use with methamphetamine. Conclusions Eight weeks of LDV/SOF cured all 25 HIV-infected men with early HCV infection, including those who were actively using drugs. Based on these results, we recommend treatment of newly HCV-infected men during early infection, regardless of drug use, to both take advantage of this 8-week treatment and to decrease further HCV transmission among this group of men.